Inclusion Criteria:

          -  Ability to understand and the willingness to provide informed consent

          -  Pathologically well-differentiated neuroendocrine tumor (i.e. grade 1 or grade 2).

          -  Primary tumor location should be known or believed to be midgut.

          -  At least one tumor in the liver that is positive with [68]Ga-DOTATATE (NETSPOT).
             Imaging must be performed within the past 6 months.

          -  Liver lesions not amendable to other therapies (surgery, ablation) and have progressed
             after treatment with octreotide/lanreotide and/or other treatments. (everolimus,
             sunitinib).

          -  Karnofsky performance status of at least 70

          -  Absolute neutrophil count of at least 1,000 cells/mm3

          -  Platelet count of at least 90,000 cells / mm3

          -  Total bilirubin ≤ 2 x the upper limit of normal when adjusted for age

          -  AST and ALT ≤ 5 x the upper limit of normal when adjusted for age

          -  Serum creatinine ≤ 1.2 mg/dl; if serum creatinine is >1.2 mg/dl nuclear GFR will used
             for potentially eligible participants.

          -  Agrees to contraception.

        Exclusion criteria:

          -  Liver tumor involvement greater than 70% by cross sectional imaging

          -  Extra-hepatic visceral and osseous metastases

          -  Concomitant therapy for tumor (except for somatostatin analogs or bisphosphonates)

          -  Previous PRRT or other liver directed therapy within 12 months of consent

          -  Women who are pregnant, breast feeding or breast pumping.

          -  Another concurrent malignancy on active therapy

          -  Previous external-beam radiation therapy to a kidney (including scatter dose)

          -  Therapeutic investigational drug within 4 weeks of therapy.

          -  Subjects for whom, in the opinion of their physician, a 24-hour discontinuation of
             somatostatin analogue therapy represents a health risk.

          -  Sandostatin LAR injection within 4 weeks or lanreotide injection within 8 weeks of
             proposed therapy.

          -  Inability to lie down supine for study procedure.

          -  Reaction to IV contrast used for the angiogram.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection requiring hospitalization, symptomatic congestive heart failure, unstable
             angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that
             would limit compliance with study requirements